Blockchain Registration Transaction Record

Regentis Biomaterials Advances GelrinC Hydrogel for Knee Cartilage Repair

Regentis Biomaterials advances GelrinC hydrogel for knee cartilage repair. Cell-free, off-the-shelf implant offers single 10-minute procedure. FDA trial over 50% enrolled.

This news matters because knee cartilage damage affects hundreds of thousands of patients annually, often leading to pain, limited mobility, and eventual osteoarthritis. Current treatments like microfracture provide only temporary relief, while cell-based therapies are costly and require multiple surgeries. GelrinC(R) offers a potential game-changer: a single, quick procedure that regenerates natural cartilage, reducing recovery time and improving long-term outcomes. If approved in the U.S., it could transform orthopedic care, offering patients a minimally invasive, off-the-shelf solution that restores knee function and quality of life, decreasing the need for repeat surgeries and potentially delaying or preventing joint replacement.